Antares Pharma Inc., of Ewing, N.J., said a written request for a type A meeting, along with a comprehensive briefing document, have been submitted to the FDA, in response to the complete response letter regarding the NDA for Xyosted, the company's drug for the treatment of testosterone deficiency (hypogonadism).